Paul Gautier

Paul Gautier

Auto-generated profile, based on publicly available information

Paul Gautier

Cardiology Department, Toulouse University Hospital , Toulouse

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MCMiloud CHERBI
Miloud CHERBI
Olivier LairezOlivier Lairez
Olivier Lairez
GBGuillaume Baudry
Guillaume Baudry
PGPaul Gautier
Paul Gautier
FRFrançois Roubille
François Roubille
CDClement Delmas
Clement Delmas
Background: Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF). However, current evidence on their efficacy and safety in this clinical setting remains limited. Methods: We performed a systematic review and meta‐analysis to assess efficacy/safety of early use of SGLT2is in AHF. PUBMED/EMBASE/Cochrane were searched from inception to May 31, 2024, for randomized controlled trials evaluating outcomes of SGLT2i early initiation in patients with AHF. Efficacy outcomes were all‐cause death and heart failure rehospitalizations. Safety outcomes included acute kidney injury, ketoacidosis, urinary tract infections, hypotension, and hypoglycemia. Early initiation was defined as performed before or shortly after discharge (within 3 days). A sensitivity analysis was conducted, including only patients with initiation before discharge. Results: Seven randomized controlled trials that enrolled 2320 patients were included. Early use of SGLT2is was associated with a significant reduction in all‐cause death (odds ratio, 0.71 [95% CI, 0.55–0.92; 95% PI, 0.55–0.98]) and HF rehospitalizations (odds ratio, 0.73 [95% CI, 0.57–0.94; 95% PI, 0.58–0.93]), even after adjusting for follow‐up duration. SGLT2i initiation before discharge yielded consistent results for efficacy outcomes. Safety outcomes could not be usefully determined because of a low events rate resulting in wide CIs. The impact of diabetic status remains basically unknown due to the small number of available randomized controlled trials investigating this population. Conclusions: Early introduction of SGLT2is in AHF improves all‐cause death and rehospitalization rates, can be performed before discharge, and should be offered to most patients with AHF.

25 June 2025 in EP Europace
Verified
Journal Article
Open access
MCMiloud CHERBI
Miloud CHERBI
PGPaul Gautier
Paul Gautier
FSFrederic Sacher
Frederic Sacher
RMRaphaël Martins
Raphaël Martins
SKSebastien Knecht
Sebastien Knecht
CDClement Delmas
Clement Delmas
Aims: Ventricular arrhythmias (VAs) occur frequently following left ventricular assist device (LVAD) implantation. However, current evidence regarding their true incidence and impact remains limited. Methods and results: We performed a systematic review and meta-analysis to assess the incidence and impact of post-LVAD VAs. PubMed/Embase/Cochrane databases were searched from inception to 1 April 2025, for studies reporting the occurrence of VAs following LVAD implantation. The primary outcome was the overall incidence of VAs. Secondary outcomes included the incidence of early (≤30 days) and late (>30 days) VAs, as well as electrical storm (ES) and their impact on all-cause mortality, assessed using incidence rate ratios (IRRs). Forty studies including 22 181 patients were analysed. The overall incidence of post-LVAD VAs was 2.43 (1.70–3.48) events per 100 person-months. Ventricular arrhythmia occurrence was significantly associated with increased all-cause mortality [IRR 1.32 (1.11–1.57)). The incidence of early VAs was 0.65 (0.48–0.88) events per 100 person-days (19.5 events per 100 patients over 30 days), and early VAs were associated with a higher risk of mortality [IRR 1.40 (1.18–1.67)]. Conversely, the incidence of late VAs was 2.05 (1.43–2.93) events per 100 person-months and was not significantly associated with mortality [IRR 0.85 (0.66–1.10)]. Electrical storm incidence was 0.44 (0.07–2.71) events per 100 person-months, significantly increasing all-cause mortality [IRR 1.34 (1.01–1.79)]. Conclusion: Ventricular arrhythmias are frequent following LVAD implantation and are associated with a significant impact on all-cause mortality—particularly when occurring early after implantation. Further studies are needed to optimize VA management and implantable cardioverter-defibrillator use.

17 November 2025 in EP Europace
Verified
Journal Article
Open access
RMRaphaël Martins
Raphaël Martins
VGVincent Galand
Vincent Galand
EFErwan Flecher
Erwan Flecher
PGPierre Groussin
Pierre Groussin
KBKerstin Bode
Kerstin Bode
MCMiloud CHERBI
Miloud CHERBI

1 May 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
SMSilvia Mas-Peiro
Silvia Mas-Peiro
GMGuillem Muntané-Carol
Guillem Muntané-Carol
JTJulien Ternacle
Julien Ternacle
GVGabriela Veiga
Gabriela Veiga
VVVictoria Vilalta
Victoria Vilalta
JRJosep Rodés-Cabau
Josep Rodés-Cabau
BACKGROUND: Cardiac structural complications (CSCs) have been recently established by the Valve Academic Research Consortium 3 consensus as a combined end point including multiple life-threatening periprocedural events following transcatheter aortic valve replacement. The objective was to assess the incidence, timing, management, and clinical impact of CSCs in the contemporary transcatheter aortic valve replacement era. METHODS: Multicenter study including consecutive patients undergoing transcatheter aortic valve replacement in 18 European and Canadian centers from 2014 to 2024. According to the Valve Academic Research Consortium 3 criteria, CSCs included cardiac structure perforation, injury or compromise, new pericardial effusion, and coronary obstruction. Data was collected in a dedicated database, and patients were followed at 30 days, 1 year, and yearly thereafter. RESULTS: Among a total of 10 541 patients, CSCs occurred in 221 (2.1%), with 126 (1.2%) patients exhibiting >1 CSC: 146 (1.4%) cardiac structure compromise events (annular rupture: 41.1%, left ventricular perforation: 26.0%; right ventricular perforation: 24.0%, other injuries: 8.9%), 150 (1.4%) new pericardial effusions, and 59 (0.6%) coronary obstructions. Up to 75.6% of CSCs occurred intraprocedurally, and 61 (27.6%) patients had conversion to open heart surgery. The incidence of CSCs remained similar throughout the study period (from 1.3% to 3.2%, median annual rate of 2.3%). Thirty-day mortality was 35.3% (52.5% among patients requiring conversion to surgery), with annular rupture associated with the highest (41.0%) mortality rate. CONCLUSIONS: About 2% of contemporary transcatheter aortic valve replacement recipients presented CSCs, which did not decrease over time, required conversion to surgery in more than one-fourth of cases, and were associated with very high periprocedural mortality rates. Further research is needed regarding potential preventive strategies and optimal surgical bailout management.

21 November 2025 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
MCMiloud CHERBI
Miloud CHERBI
PGPaul Gautier
Paul Gautier
KBKarim Benali
Karim Benali
RMRaphael Martins
Raphael Martins
PMPhilippe Maury
Philippe Maury
CDClement Delmas
Clement Delmas

14 March 2026 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
RMRaphael Martins
Raphael Martins
VGVincent Galand
Vincent Galand
EFErwan Flecher
Erwan Flecher
PGPierre Groussin
Pierre Groussin
KBKerstin Bode
Kerstin Bode
MCMiloud CHERBI
Miloud CHERBI